Publication

Progression of albuminuria in patients with sickle cell anemia: a multicenter, longitudinal study

Downloadable Content

Persistent URL
Last modified
  • 05/15/2025
Type of Material
Authors
    Omar Niss, University of CincinnatiAdam Lane, University of CincinnatiMonika R. Asnani, University of the West IndiesMarianne Yee, Emory UniversityAshok Raj, University of LouisvilleSusan Creary, Nationwide Children's HospitalCourtney Fitzhugh, National Heart, Lung, and Blood InstitutePrasad Bodas, Akron Childrens HospSantosh L. Saraf, University of IllinoisSharada Sarnaik, Children's Hospital of MichiganPrasad Devarajan, University of CincinnatiPunam Malik, University of Cincinnati
Language
  • English
Date
  • 2020-04-14
Publisher
  • American Society of Hematology
Publication Version
Copyright Statement
  • © 2020 American Society of Hematology. All rights reserved.
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 4
Issue
  • 7
Start Page
  • 1501
End Page
  • 1511
Grant/Funding Information
  • This work was supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants R34 HL 108752 and 1UO1 HL117709-01 (P.M.).
  • O.N. was the recipient of a Translational Research Scholar Award (U01HL117709).
Supplemental Material (URL)
Abstract
  • Sickle cell nephropathy results in chronic kidney disease (CKD), which is associated with significant morbidity and mortality in sickle cell anemia (SCA). Albuminuria is an early manifestation of sickle nephropathy; however, little is known about progression of albuminuria or its correlation with glomerular filtration rate (GFR) decline or CKD. We studied nephropathy progression in 303 SCA participants in a prospective, multicenter, longitudinal study. We collected steady-state urine and serum samples yearly and assessed albumin/creatinine ratio (ACR), estimated GFR (eGFR), and SCA and nephropathy biomarkers. Participants with albuminuria (ACR $30 mg/g) for $2 annual measurements were classified as having persistent albuminuria (PA). At baseline (mean age, 21 years; range, 2-64 years), 32% had albuminuria. In longitudinal multivariate analysis, ACR was associated with sex, anemia, older age, and higher bilirubin and kidney injury molecule-1 levels. Albuminuria increased with age by 3.5 mg/g per year (P , .0001). Of 175 participants with $3 annual samples, 81% with baseline albuminuria $100 mg/g developed PA. Decreased eGFR and adult CKD were associated with PA (P 5 .002 and P 5 .02, respectively), but not with baseline albuminuria. Rate of eGFR decline was steeper among adults (but not children) with albuminuria, compared with those without (P 5 .02). Participants with PA were more likely to have rapid eGFR decline compared with those without (P 5 .03). In this longitudinal study, albuminuria progressed with age, and adults with albuminuria had worse eGFR decline than those without. Albuminuria $100 mg/g predicted PA, which was associated with rapid eGFR decline and CKD development in adults with SCA. This trial was registered at www.clinicaltrials.gov as #NCT02239016.
Author Notes
  • Correspondence: Omar Niss, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, MLC 7015, Cincinnati, OH 45229; e-mail: omar.niss@cchmc.org
Keywords
Research Categories
  • Health Sciences, Medicine and Surgery
  • Health Sciences, Human Development
  • Biology, Cell
  • Health Sciences, Oncology

Tools

Relations

In Collection:

Items